Evidence map›Paper›PMID 39766101›Full record

ArticleCancers2024

Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy.

Mishfak A Mohamed Mansoor, Xiang Zhu, Sarah Aslam Ashiqueali, Md Tanjim Alam, Hanna Winiarska, Pawel Pazdrowski, Filip Kaminski, Alicja Copik, Michal M Masternak, Barbara Kuznar-Kaminska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mishfak A Mohamed MansoorBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0002-4930-0552
Xiang ZhuBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0003-0398-5442
Sarah Aslam AshiquealiBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0003-1980-1054
Md Tanjim AlamBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
Hanna WiniarskaDepartment of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
Pawel PazdrowskiMedical Faculty, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
Filip KaminskiMedical Faculty, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
Alicja CopikBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0003-4109-5539
Michal M MasternakBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
Barbara Kuznar-KaminskaBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.ORCID 0000-0001-7236-5023

Funding

Florida Department of Health 24A12National Science Center UMO-2023/51/B/NZ5/00498National Science Foundation 2317758
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer immunotherapycancer prognosislung cancermicroRNAsPD-1 blockade

Identifiers

PMID39766101
PMCPMC11674096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.